News | Antiplatelet and Anticoagulation Therapies | November 06, 2017

Six Months of DAPT Non-Inferior to Twelve in STEMI Patients Receiving Drug-Eluting Stents

Study finds patients may not benefit from recommended longer periods of DAPT

Six Months of DAPT Non-Inferior to Twelve in STEMI Patients Receiving Drug-Eluting Stents

November 6, 2017 —  The first trial to evaluate the safety of dual antiplatelet therapy (DAPT) for less than 12 months in ST-elevation myocardial infarction (STEMI) found six months of DAPT was non-inferior to 12 months among patients treated with second-generation drug-eluting stents (DES).

Findings were reported at the 29th annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium sponsored by the Cardiovascular Research Foundation (CRF), Oct. 29-Nov. 2 in Denver.

International guidelines recommend 12 months of DAPT for STEMI patients after primary peructaneous coronary intervention (PCI) with DES due to ongoing atherothrombotic risk. While longer duration DAPT therapy reduces the risk of ischemic events, it is also associated with a higher risk of major bleeding that can sometimes be fatal. Second-generation DES have a lower stent thrombosis risk than their predecessors, questioning the need for an extended duration of DAPT.

DAPT STEMI was a prospective, randomized trial designed to evaluate whether six months of DAPT was non-inferior to 12 months in event-free patients at six-month follow-up after primary PCI. The study enrolled 1,100 STEMI patients who underwent primary PCI with a second-generation zotarolimus-eluting stent. Those who were event-free at six months and agreed to continue with the study (N=870) were randomized to single antiplatelet therapy (SAPT, N=433) or DAPT (N=437). Baseline and procedural characteristics were similar in both arms.

The study’s primary endpoint was a patient-oriented composite of all-cause mortality, any myocardial infarction, any revascularization, stroke or thrombolysis in myocardial infarction (TIMI) major bleeding at 18-month follow-up after randomization (i.e. two years after primary PCI). The primary endpoint occurred in 4.8 percent of the SAPT group versus 6.6 percent for the DAPT group {HR 0.73; 95% CI (0.41-1.27); P= 0.26; Pnon-inferiority=0.004}. The incidences of the individual components of the primary endpoint were as follows:

  • Mortality: 0.7 percent in SAPT vs. 1.4 percent in DAPT {HR 0.51; 95% CI (0.13-2.02); P=0.33};
  • Myocardial infarction: 1.8 percent vs. 1.8 percent {HR 1.02; 95% CI (0.38-2.71); P=0.97;
  • Revascularization: 3 percent vs. 3.9 percent {HR 0.87; 95% CI (0.42-1.83); P=0.72;
  • Stroke: 0.7 percent vs. 0.7 percent {HR 1.02; 95% CI (0.21-5.03); P=0.99; and
  • TIMI major bleeding: 0.2 percent vs. 0.5 percent {HR 0.51; 95% CI (0.05-5.57); P=0.58.

“For the first time in the modern DES era, this trial indicates that STEMI patients, similar to stable angina patients, may not benefit from prolonged DAPT therapy beyond six months as currently recommended,” said Elvin Kedhi, M.D., Ph.D., head of the Interventional Cardiology and Clinical Research and Innovation at Isala Hartcentrum in Zwolle, The Netherlands. “This sets the stage for further dedicated research on this important topic.”

The DAPT STEMI trial was funded by Maasstad Cardiovascular Research. Kedhi reported receiving consulting fees/honoraria or institutional grants from Medtronic, Abbott, Meril and OrbusNeich.

Watch a VIDEO interview on tthis study

For more information:


Related Content

TCT 2017 Late-breaking Clinical Trial Presentations



Related Content

CorInnova Awarded 2017 InnoSTARS Prize for EpicHeart Soft Robotic Heart Assist Device
News | Artificial Heart| December 11, 2017
CorInnova Inc. recently announced it was awarded second prize in the “2017 InnoSTARS” life science competition for its...
ECG Study of NBA Players Shows Need for Sport-Specific Normative Data and Guidelines
News | ECG| December 08, 2017
Cardiologists at NewYork-Presbyterian/Columbia University Irving Medical Center compared electrocardiographic findings...
New Study Suggests Protein Could Protect Against Coronary Artery Disease

Patients with no obstructed blood flow in the coronary arteries had higher levels of CXCL5 (blue) compared to patients with moderate levels (green) or lower levels (yellow) of CXCL5, who had increased severity of coronary obstructions (indicated by the arrows). Credit: Schisler lab

News | Cardiac Diagnostics| December 07, 2017
December 7, 2017 — The buildup of plaque in the heart’s arteries is an unfortunate part of aging.
Edwards Acquires Harpoon Medical
News | Heart Valve Technology| December 07, 2017
December 7, 2017 — Edwards Lifesciences Corp.
Robocath Receives $1.5 Million in Capital for Advancement of R-One Robotic System
News | Robotic Systems| December 06, 2017
December 6, 2017 — French company Robocath, which designs and develops...
New data on the Corvia intra-atrial shunt to treat diastolic heart failure were presented at the recent 2017 American Heart Association (AHA) Scientific Sessions. It was the most popular story in November.

New data on the Corvia intra-atrial shunt to treat diastolic heart failure were presented at the recent 2017 American Heart Association (AHA) Scientific Sessions. It was the most popular story in November.

Feature | December 06, 2017 | Dave Fornell
Here is the list of the most popular articles and videos on the Diagnostic and Interventional Cardiology (DAIC) magaz
New Tool Predicts Risk of Heart Attack in Older Surgery Patients
News | Cardiac Diagnostics| December 05, 2017
A tool designed to more accurately predict the risk of heart attack in older patients undergoing non-cardiac surgery...
Screening for Critical Congenital Heart Disease at Birth Saves Lives
News | Congenital Heart| December 05, 2017
Infant deaths from critical congenital heart disease (CCHD) decreased more than 33 percent in eight states that...
Toshiba Medical Rolls Out Interactive Learning Tools for Ultrasound and Vascular Training
News | Ultrasound Imaging| December 04, 2017
Toshiba Medical, a Canon Group company, introduced new educational tools and interactive learning resources to help...
Philips Azurion Platform Improves Clinical Workflow and Staff Experience Benefits
News | Angiography| December 04, 2017
Philips recently announced the results of a comprehensive, independent, two-year study demonstrating the clinical...
Overlay Init